Drugs / HRS-9813
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT07229716 | Apr → Jun 2026 | pulmonary fibrosis | Guangdong Hengrui Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT06939504 | May → Jun 2025 | pulmonary fibrosis | Guangdong Hengrui Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT06821464 | Feb → Jul 2025 | idiopathic pulmonary fibrosis | Guangdong Hengrui Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT06514963 | Jul 2024 → Jan 2025 | — | Guangdong Hengrui Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06555068 | Aug 2024 → Dec 2027 expected | breast cancer | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07192939 | Oct 2025 → Jun 2028 expected | interstitial lung disease | Guangdong Hengrui Pharmaceutical Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HRS-9813 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07229716 ↗ |
| Route | Oral | “Single and Multiple Ascending Oral Doses” NCT06514963 ↗ |